Cowen Reiterates Outperform on Ironwood Pharma (IRWD) Following IW-1973 Data
Get Alerts IRWD Hot Sheet
Rating Summary:
14 Buy, 11 Hold, 2 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Cowen reiterated an Outperform rating and $20.00 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) following the company's presentation of additional data from its Phase IIa study testing IW-1973 in HFpEF.
IW-1973 led to improvements in insulin resistance as shown by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) score decline by an average of 36% during the 14-day trial period, compared to 13% in patients taking a placebo.
For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.
Shares of Ironwood Pharmaceuticals closed at $19.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ironwood Pharma (IRWD) Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease
- Hennes & Mauritz AB (HMB:SS) (HNNMY) PT Raised to SEK190 at RBC Capital, 'showing some promising signs '
- UniFirst Corp (UNF) PT Raised to $186 at UBS
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!